A New Milestone in Dry Mouth Treatment
Patients suffering from the symptoms of Sjogren’s syndrome now have a new way to manage their condition. Cosette Pharmaceuticals, Inc. has officially announced that the U.S. Food and Drug Administration (FDA) has granted approval for Evoxac (cevimeline HCl) oral solution (15 mg/5 mL). This approval marks an important advancement for those who require an alternative to solid oral dosage forms.
What is Evoxac?
Evoxac is a cholinergic agonist designed to stimulate saliva production. It is specifically indicated for the treatment of symptoms of dry mouth in patients with Sjogren’s syndrome. By providing a liquid formulation, this new option offers flexibility for patients who may have difficulty swallowing tablets or capsules.
Key Details of the Approval
- Product Name: Evoxac (cevimeline HCl) oral solution
- Dosage Strength: 15 mg/5 mL
- Indication: Treatment of symptoms of dry mouth in patients with Sjogren’s syndrome
- Developer: Cosette Pharmaceuticals, Inc.
This approval highlights the ongoing commitment within the pharmaceutical industry to address the diverse needs of patients, ensuring that effective therapies are accessible in formats that suit individual health requirements. Patients are encouraged to consult with their healthcare providers to discuss if this new oral solution is the right addition to their treatment plan.
Source: Read More